Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Published Online
on June 29, 2009

Hypertension. 2009
Published online before print June 29, 2009, doi: 10.1161/HYPERTENSIONAHA.109.129460
A more recent version of this article appeared on August 1, 2009
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
54/2/359    most recent
HYPERTENSIONAHA.109.129460v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Park, J.-K.
Right arrow Articles by Fiebeler, A.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Park, J.-K.
Right arrow Articles by Fiebeler, A.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Related Collections
Right arrow Animal models of human disease
Right arrow Genetically altered mice
Right arrow Other Vascular biology

Submitted on January 19, 2009
Revised on February 8, 2009

Growth Arrest Specific Protein 6 Participates in DOCA-Induced Target-Organ Damage

Joon-Keun Park; Stefanie Theuer; Torsten Kirsch; Carsten Lindschau; Uwe Klinge; Arnd Heuser; Ralph Plehm; Mihai Todiras; Peter Carmeliet; Hermann Haller; Friedrich C. Luft; Dominik N. Muller; and Anette Fiebeler*

From the Department of Internal Medicine-Nephrology (J.-K.P., T.K., C.L., H.H., A.F.), Hannover University Medical School, Germany; the Experimental and Clinical Research Center (S.T., C.L., A.H., R.P., M.T., F.C.L., D.N.M., A.F.), Franz Volhard Clinic HELIOS Klinikum-Berlin and Max Delbrück Center for Molecular Medicine, Medical Faculty of the Charité, Germany; University Hospital RWTH-Aachen and Helmholtz Institute (U.K.), Aachen, Germany; and the Versalius Research Center, VIB (P.C.) and the Versalius Research Center, K.U. (P.C.), Leuven, Belgium.

* To whom correspondence should be addressed. E-mail: fiebeler{at}charite.de.

Abstract—Growth arrest–specific protein 6 (Gas 6) is involved in inflammatory kidney diseases, vascular remodeling, cell adhesion, and thrombus formation. We explored a role for Gas 6 in aldosterone-induced target organ damage. We observed that Gas 6 was upregulated in rats with high aldosterone levels. Mineralocorticoid receptor blockade prevented target organ damage and decreased the elevated Gas 6 expression. Vascular smooth muscle cells given aldosterone increased their Gas 6 expression in vitro. To test the pathophysiological relevance, we investigated the effects of deoxycorticosterone acetate (DOCA) on Gas 6 gene-deleted (-/-) mice. After 6 weeks DOCA, Gas 6-/- mice developed similar telemetric blood pressure elevations compared to wild-type mice but were protected from cardiac hypertrophy. Cardiac expression of interleukin 6 and collagen IV was blunted in Gas 6-/- mice, indicating reduced inflammation and fibrosis. Gas 6-/- mice also had an improved renal function with reduced albuminuria, compared to wild-type mice. Renal fibrosis and fibronectin deposition in the kidney were also reduced. Gas 6 deficiency reduces the detrimental effects of aldosterone on cardiac and renal remodeling independent of blood pressure reduction. Gas 6 appears to play a role in mineralocorticoid receptor-mediated target organ damage. Furthermore, because warfarin interferes with Gas 6 protein expression, the findings could be of clinical relevance for anticoagulant choices.


Key words: Gas 6 • aldosterone • cardiac hypertrophy • albuminuria • inflammation